Recent Finacing
Recent Raise
Novasenta develops antibody-based cancer immunotherapies targeting the tumor microenvironment using a proprietary single-cell RNA analysis platform, machine-learning-driven target discovery, in vivo validation, and T-cell-focused pipeline.
